@therestoreclinic's TRT hybrid protocol claims examined

What did @therestoreclinic actually say?

The creator described a "TRT hybrid protocol" as combining testosterone injections with a transdermal testosterone product. Their specific pitch: if a man on injections has good energy and mood but still has low libido, adding "a little click of that transdermal sometimes is what it takes to get the job done." They were careful to note this approach is "not for everybody."

This is a real clinical concept, not something invented for TikTok. The combination approach exists in practice, and the reasoning given, that different delivery routes may produce different hormonal profiles, is at least partially grounded in how testosterone pharmacokinetics actually work. The creator did not overclaim, did not name specific doses, and appropriately flagged that this is a targeted solution for a specific presentation. That restraint matters on a platform where hormone content usually goes sideways fast.

Does the science back this up?

Partially, yes. The underlying logic relies on the idea that transdermal testosterone produces a different hormonal byproduct profile than injections, specifically a higher ratio of dihydrotestosterone, or DHT, which is more androgenic and has been linked to libido effects. That part has real support.

Transdermal testosterone application to scrotal skin in particular produces substantially elevated DHT levels compared to intramuscular injections. Swerdloff et al. (2000, Journal of Clinical Endocrinology and Metabolism) documented meaningfully higher DHT-to-testosterone ratios with transdermal versus injectable routes. DHT has a higher binding affinity for androgen receptors than testosterone itself, and some research suggests DHT plays a more direct role in sexual function than total testosterone alone. Traish et al. (2014, Journal of Sexual Medicine) reviewed evidence that DHT contributes independently to erectile function and libido in men. However, it is worth noting that the clinical evidence for hybrid protocols specifically, meaning formal studies of combining routes rather than switching between them, is sparse. Most of what supports this approach is pharmacokinetic reasoning and clinical observation, not randomized controlled trial data.

What did they get wrong (or right)?

They got the core pharmacological reasoning roughly right. Transdermal testosterone does tend to produce higher DHT levels than injections, and DHT is plausibly linked to libido. Credit where it is due.

What the video leaves out is meaningful, though. First, the creator does not mention where the transdermal is being applied, and that matters enormously. Scrotal application produces dramatically higher DHT conversion than application to the arm or abdomen, as documented in Ly et al. (2004, Clinical Endocrinology). A "click" of transdermal on the forearm versus the scrotum are functionally different interventions. Second, the video treats libido as a simple androgen-deficiency problem, but low libido in men on TRT can involve estradiol imbalance, prolactin elevation, sleep disruption, relationship factors, or medication side effects. Adding more testosterone delivery is not always the right answer, and presenting it as a go-to fix is an oversimplification. Third, adding a second delivery method increases monitoring complexity, skin DHT exposure for partners, and cost. None of that gets mentioned.

What should you actually know?

If you are on testosterone injections and still struggling with libido, it is worth a real conversation with a clinician before adding anything. Libido on TRT is not a one-variable problem.

A few things worth knowing before assuming a hybrid protocol is your answer. Estradiol levels should be checked first. High estrogen, which is common in men on higher-dose testosterone protocols, is one of the more common libido suppressors and is frequently overlooked. Morgentaler et al. (2015, Mayo Clinic Proceedings) noted that both low and high estradiol correlate with sexual dysfunction in men on TRT. DHT-elevating approaches through transdermal testosterone are not without trade-offs. Elevated DHT is associated with accelerated hair loss in genetically susceptible men and has theoretical implications for prostate tissue, though the clinical significance remains debated. Partner exposure to transdermal testosterone is a real documented risk, particularly with gel formulations applied to skin that a partner may contact. The FDA has issued warnings on this. Finally, "hybrid protocol" is not a standardized medical term. It means different things at different clinics, and the absence of formal trial data means you are largely in clinical-experience territory, not evidence-based protocol territory.